The primary endpoint was not confirmed as evaluating TILs related to viable tumour tissue was compromised by extensive tumour necrosis and low carcinoma following CaEP treatment, which was also the case for evaluation of PD-L1-expression. The gene discussed is CD274; the disease is carcinoma.